

Adiponectin during pregnancy prevents vascular dysfunction in offspring from mouse obese dams

Molly Murphy,¹ Jerad H. Dumolt,² Theresa L. Powell,² Thomas Jansson,¹ and Ramón A. Lorca¹

¹ DIVISION OF REPRODUCTIVE SCIENCES, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS
² DEPARTMENT OF PEDIATRICS, UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS




University of Colorado
Anschutz Medical Campus

BACKGROUND

Maternal obesity has been associated with increased risk of metabolic and cardiovascular disease in the offspring, including impaired vasodilation. Adiponectin (ADN) is an adipokine that regulates metabolism, insulin sensitivity, and vascular function. Plasma levels of ADN are lower in obese pregnancies compared to lean controls. Moreover, ADN supplementation has been associated with improved fetal growth, metabolism, cardiac function, and placental function. We hypothesized that increasing the circulating ADN levels in obese pregnant mice could reverse the effects of maternal obesity on offsprings' vascular function.

METHODS


Adult female mice were fed with either control (CON, n=5) or obesogenic (OB, n=6) diet until the OB group gained 25% of their initial body weight and mated with CON males. A mini-osmotic pump was subcutaneously implanted in all pregnant dams at late pregnancy (embryonic day 14.5). CON dams received a continuous infusion of phosphate saline buffer (PBS, n=5), whereas OB females received either PBS (n=3) or ADN (0.62 µg g⁻¹ day⁻¹, n=3). Dams were maintained on their respective diets during pregnancy and throughout lactation. After weaning, offspring were fed CON diet.



Between seven and nine months of age, adult offspring's mesenteric arteries (MSA) were dissected and mounted in a wire myograph. Contralateral responses to phenylephrine or endothelin-1 and dilator responses to acetylcholine (ACh), bradykinin (BK) or the nitric oxide donor sodium nitroprusside (SNP) were determined in the offspring of CON-PBS, OB-PBS and OB-ADN dams. Concentration-response curves were compared by one-way ANOVA.


RESULTS

1 Mesenteric artery (MeA) responses to vasoconstrictors.




Concentration-response curves of acetylcholine (ACh), A) or bradykinin (BK, C) in MeA of offspring from control dams (CON-PBS, closed symbols), obese dams (OB-PBS, open symbols) or obese dams supplemented with adiponectin (OB-ADN, gray symbols), presented as percentage of maximal KCl response (K_{max}). Numbers in parenthesis are the number of mice, symbols are mean values ± SEM. Analysis of curves in A and C, respectively. * p < 0.05 and ** p < 0.01 by one-way ANOVA.


3 ACh-dependent vasodilation is partially mediated by prostaglandin signaling in MeA from adult offspring.



4 MSA vasodilation induced by a nitric oxide donor, but not AMPK activation, is reduced by ADN exposure in utero.



2 Acetylcholine-dependent vasodilation is reduced by maternal obesity and restored by adiponectin supplementation in MeA from adult offspring.



SUMMARY & CONCLUSIONS

- MsA responded to the vasoconstrictors phenylephrine and endothelin-1 similarly among groups.
- MsA vasodilatory responses to ACh were reduced by maternal obesity and restored in offspring from obese dams supplemented with ADN.
- BK responses were not different among groups.
- SNP-evoked vasodilation was reduced in offspring from obese dams supplemented with ADN.
- These results highlight a role of the reduced levels of ADN seen during obese pregnancies in the vascular dysfunction of the offspring.
- The ADN supplementation during obese pregnancy showed prevention of these vascular effects on the offspring. Future studies are warranted to further explore the putative beneficial effects of ADN in pregnancies affected by obesity.

REFERENCES

1. Catalano PM, Bramer K. Obesity and pregnancy mechanisms of short term and long term adverse consequences for mother and child. *Prog* 2017;88:1-10.
2. 2017;88:1-10.
3. 2017;88:1-10.
4. 2017;88:1-10.
5. 2017;88:1-10.
6. 2017;88:1-10.
7. 2017;88:1-10.
8. 2017;88:1-10.
9. 2017;88:1-10.
10. 2017;88:1-10.
11. 2017;88:1-10.
12. 2017;88:1-10.
13. 2017;88:1-10.
14. 2017;88:1-10.
15. 2017;88:1-10.

ACKNOWLEDGEMENTS

We thank Dr. Owen Vaughan, Brea Diamond, Kelsey Berner, and Julie Houck for assistance.

This work was partially funded by the National Institutes of Health grants R03 HD101659 and R21 HD102628 (to R.A.L.).